



# **AE-PCOS**

ANDROGEN EXCESS & PCOS SOCIETY

## **Joint AEPCOS/Endocrine Society Update Meeting in Orlando @ ENDO 2017**

**GUT, MICROBIOME AND FAT: ORIGINS OF PCOS METABOLIC DISEASE?  
ORANGE COUNTY CONVENTION CENTER, ORLANDO, FL, USA, MARCH 31, 2017**

### ***CALL FOR ABSTRACTS***

#### **Submission Deadline**

**11:00 PM (2300 HRS) PST, FEBRUARY 24<sup>th</sup>, 2017**

You are invited to submit abstracts of your original research to be considered for presentation at the Joint AEPCOS/Endocrine Society Update Meeting in Orlando @ ENDO 2017. These abstracts can also have been submitted to ENDO 2017 for separate consideration.

To be considered for presentation at this AEPCOS Update meeting, your abstract must be submitted no later than FEBRUARY 24<sup>th</sup>, 2017, 11:00 pm (2300 hrs.) PST and should be related to the matter of the meeting.

All abstracts will be reviewed by a blinded scientific committee nominated by AE-PCOS Update Meeting Committee.

## INSTRUCTIONS FOR SUBMISSION OF ABSTRACTS

Please read the following guidelines thoroughly before preparing your abstract.

1. The presenter is required to register for Joint AEPPOS/Endocrine Society Update Meeting in Orlando @ ENDO 2017 on submission of the abstract (see [www.ae-society.org](http://www.ae-society.org)).
2. The abstract should be informative as possible (see [Sample Abstract](#) below).
3. The AE-PCOS Society reserves the right to decide on the form of presentation in the interests of the scientific program. All abstracts selected for this 2017 Update meeting, however, will be short oral presentations. It is understood that the first author of the abstract will serve as the presenter, and that the presenter will be registered for Joint AEPPOS/Endocrine Society Update Meeting in Orlando @ ENDO 2017
4. Abstracts should be emailed to [info@ae-society.org](mailto:info@ae-society.org), by 11:00 pm (2300 hrs.) PST, February 24<sup>th</sup>, 2017.

### SAMPLE ABSTRACT


**LOW PREVALENCE OF THE V281L MUTATION OF CYP21 AMONG WOMEN WITH THE POLYCYSTIC OVARY SYNDROME (PCOS).** Smith JG (1), Jones EB (2), Bartley MRD (2).

(1) Dept. of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA; and (2) Dept. of Ob/Gyn, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Familial aggregation indicates that genetic factors are important in the pathogenesis of PCOS. In searching for PCOS genes, we and others have reported an increased frequency of heterozygosity for CYP21 mutations, especially the V281L missense mutation, among children with premature pubarche (PP), adolescent girls with hyperandrogenism, and a small cohort of women with PCOS. To determine whether the frequency of the V281L mutation of CYP21 is actually increased in PCOS, and whether this increase is associated with adrenal androgen (AA) excess, we determined the presence of this mutation in 170 women with PCOS and excessive AA secretion, 152 women with PCOS and normal AA secretion, and 94 healthy adult female controls from the Southeastern U.S. Genotyping was performed by PCR followed by allele specific RFLP analysis. PCOS was defined by the presence of oligo-ovulation in combination with clinical evidence of hyperandrogenism (e.g. hirsutism) and/or hyperandrogenemia (e.g. supranormal free testosterone levels), after the exclusion of related disorders, including 21-hydroxylase deficient non-classic adrenal hyperplasia. Our results indicate that in the population studied two women with PCOS, one with AA excess and one without, were heterozygous carriers of V281L. None of the control women carried this CYP21 mutant allele. We can conclude that the V281L mutation of CYP21 is relatively rare among the population of PCOS women studied, regardless of presenting AA levels. Although we cannot exclude the possibility that other CYP21 mutant alleles may be more common in this population, differences in ethnic background may explain the low frequency of heterozygosity for the V281L mutation in this population of PCOS women compared to previous reports. Furthermore, heterozygosity for CYP21 mutations may play a greater role in PP rather than in PCOS (supported in part by NIH grants 2-R01-HD30000 to JGS and R21-HD30000 to MRDB).

**Special instructions:**

- 1) Use font Times Roman 11.
- 2) Use single space.
- 3) The title should be in caps and bolded.
- 4) Authors should be listed as follows: Last name first name initials. Affiliation key should follow each name in superscript, e.g., Smith JG<sup>(1)</sup>, Jones EB<sup>(2)</sup>.
- 5) Affiliations should note department/division, institution, city, state or province, and country. Each affiliation should be preceded by key in superscript, e.g., (1) Dept. of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA; and (2) Dept. of Ob/Gyn, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- 6) A space should be placed between the affiliations and the body of the abstract.
- 7) Please limit your abstract to the space provided.
- 8) Funding sources should be acknowledged at the end of the abstract, in parentheses.
- 9) The form type used will not accept symbols, superscripts, or subscripts so please do not use these, e.g., do not use “ $\beta$ ”, instead type “Beta”.



**ABSTRACT SUBMISSION FORM**

*DEADLINE FOR SUBMISSION: 11:00 PM (2300 HRS) PST, FEBRUARY 24<sup>TH</sup>, 2017*

Abstracts should be emailed to [info@ae-society.org](mailto:info@ae-society.org)

**Title:**  
**Authors:**  
**Affiliations:**  
**Abstract:**

**Please complete all required fields and submit by email to [info@ae-society.org](mailto:info@ae-society.org).**

I am a member of the AE-PCOS Society.

I am a member of Endocrine Society

\_\_\_\_\_  
Presenter Name

\_\_\_\_\_  
Date

**Please complete contact information and attach to your electronic submission. You will be assigned an abstract number and notified using the information you list below. Please ensure that all information is correct.**

<i>Name (Last, First):</i> _____	
<i>Specialty</i> _____	
<i>Institution</i> _____ _____	
<b><i>Mailing Address:</i></b>	
Street Address _____	
_____	_____
City/State	Country
<i>Email:</i> _____	

**IF YOU HAVE ANY QUESTIONS PLEASE CONTACT BY EMAIL**  
[info@ae-society.org](mailto:info@ae-society.org)